Tagged with R

Africa Diabetes is a significant, and growing, problem in Africa, making access to insulin products a regional imperative. Some important progress is being made, including a new deal between US giant Eli Lilly and Egyptian group EVA Pharma. The agreement will allow Lilly products to be manufactured in, and for, the…

Europe Edward Mc Gettrick and Sharon Gorman of Pfizer, writing in the January 2023 edition of DIA’s Global Forum magazine, examine the scope and impact of the European Union’s new Regulation on Health Technology Assessment.   In December 2021, the European Commission (EC) adopted the Regulation on Health Technology Assessment (EU HTA…

Greece Fresh from the recent announcement of a massive EUR 356 million investment package for the 2021-2027 period to expand and modernise its production and R&D footprints, DEMO Pharma’s Dimitris Demos outlines how the family-owned firm rode out the financial crisis years and what is powering its growth today. Demos also…

Greece The European Union’s decision to mitigate the effects of the COVID-19 pandemic by launching its Recovery and Resilience Facility (RRF) and moving away from its past austerity policies is particularly significant for Greece. Severely hit by the financial crisis a decade ago and thrown off its course to recovery by…

Global Brendan Shaw looks ahead to the rest of 2023, identifying five key trends to watch out for in the healthcare and life sciences sector. With the worst of COVID-19 now in the rear-view mirror for much of the world, Shaw questions whether the lessons and progress that the pandemic brought…

Egypt The leading company in the Egyptian pharma market by volume, the Egyptian International Pharmaceutical Industries Company (EIPICO) is now making a region-first move into biologicals and biosimilars manufacturing to power its future growth as well as expanding its international footprint.   Biologics: A Big Leap Forward The company’s plan to…

Egypt Three country managers with a recent experience of bringing new products from their company’s global portfolio into Egypt – and with big plans for more launches in coming years – outline how the product launch process has improved and why government stakeholders are more receptive than ever to industry innovations.…

Global Antimicrobial resistance (AMR), or the resistance of pathogens to antibiotics, antivirals, antifungals and antiparasitics has been declared by the World Health Organization (WHO) as one of the top 10 global public health threats and was associated with the death of some 5 million people in 2019. The latest WHO report…

China A roundup of some of the biggest healthcare and pharma news from China including the exclusion of Pfizer’s Paxlovid from the country’s national insurance coverage, CanSino’s promising mRNA booster trial results, WuXi Biologics and GSK’s T-cell engager deal, Biocytogen and Hansoh’s antibody collaboration …   Pfizer CEO rules out generic…

Africa While HIV has shifted from a death sentence to a manageable disease in most developed nations, there are several reasons why it still represents a huge global issue. It remains highly infectious and difficult to detect in the early stages of infection, while existing treatments are unavailable or too expensive…

Germany Home to Europe’s largest pharma market, a host of industry giants, a thriving biotech scene, and a public healthcare system undergoing significant reform, Germany is indisputably one of the world’s most important life science nations.   An overview of the pharma industry in Germany. Made with Visme Infographic Maker   The…

Portugal Part of PharmaBoardroom’s new country-focused series on market access and health technology assessment (HTA), this piece gives the lowdown on post-market approval processes and regulations in Portugal. Buy The Pharma Legal Handbook: Market Access & HTA – Portugal here for £359.   What are the pricing principles and processes in your…